EYLEA HD Drug Profile

Summary for Tradename: EYLEA HD

High Confidence Patents:	44
Applicants:	1
BLAs:	1

Pharmacology for EYLEA HD

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EYLEA HD Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EYLEA HD Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355		2037-03-28	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355		2036-03-10	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355		2038-10-12	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355		2038-10-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for EYLEA HD Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355		2037-12-21	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355		2035-11-23	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355		2036-11-15	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355		2035-03-17	Patent claims search

International Patents for EYLEA HD

Country	Patent Number	Estimated Expiration
Chile	2023002512
Malaysia	193353
Australia	2016228990
Israel	318471

Supplementary Protection Certificates for EYLEA HD

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2013C/029	Belgium		PRODUCT NAME: AFLIBERCEPT; AUTHORISATION NUMBER AND DATE: EU/1/12/197/001 20121126
C201300026	Spain		PRODUCT NAME: AFLIBERCEPT; NATIONAL AUTHORISATION NUMBER: EU/1/12/797/001-002; DATE OF AUTHORISATION: 20121122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/797/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20121122
PA2013009,C1183353	Lithuania		PRODUCT NAME: AFLIBERCEPTUM; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122
C300588	Netherlands		PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122

Market Dynamics and Financial Trajectory for EYLEA HD

Last updated: April 12, 2026

What is EYLEA HD?

EYLEA HD (aflibercept) is an advanced formulation of the anti-VEGF biologic used primarily to treat diabetic macular edema (DME), wet age-related macular degeneration (AMD), and others. The "HD" version, marketed as EYLEA High Dose, increases the concentration of active ingredient to potentially extend dosing intervals and improve patient outcomes.

Development and Regulatory Milestones

• FDA Approval: October 2020 for treatment of diabetic macular edema (DME).
• EMA Approval: December 2020 in the European Union.
• Indications: DME, wet AMD, and other retinal vascular diseases.

Market Overview

Size and Growth

• Global intravitreal anti-VEGF agents market: $8.2 billion in 2022.
• Compound annual growth rate (CAGR): 7.2% (2022-2027) according to MarketsandMarkets.
• DME segment: expected to grow from $3.2 billion in 2022 to $4.8 billion in 2027.

Key Competitors

Product	Mechanism	Approved Indications	Market Share (2022)
EYLEA (aflibercept)	Anti-VEGF antibody	AMD, DME, RVO	45%
Lucentis (ranibizumab)	Anti-VEGF antibody	AMD, DME, RVO	40%
Beovu (brolucizumab)	Anti-VEGF antibody	AMD	10%
Off-label steroids	Corticosteroids	DME (less common now)	5%

EYLEA maintains a leading position due to its broad indication profile and longer dosing intervals.

Market Dynamics Influences

Clinical Advantages

• EYLEA HD’s higher dose formulation allows dosing every 12 weeks versus 8-week intervals for standard formulations.
• Clinical trials (VIVID-DME and VISTA-DME) demonstrated non-inferior visual acuity improvements with less frequent injections.

Physician Adoption

• Increasing preference for less frequent dosing regimens.
• Comfort with established EYLEA usage broadens acceptance.
• Early clinical data supports improved outcomes with HD formulations.

Reimbursement Policies

• Coverage varies by region, with insurers favoring treatments reducing injection frequency.
• Medicare and private insurers in the US reimburse based on standard dosages; adjustments are continual as new data emerges.

Market Penetration and Patient Demand

• Growing prevalence of diabetic retinopathy and AMD.
• Aging populations, especially in North America and Europe, underpin increased demand.
• Off-label use of steroids for DME declines as anti-VEGF options improve.

Financial Trajectory Predictions

Revenue Estimates

Year	Estimated Revenue	Growth Rate	Source/Modeling Assumptions
2022	$350 million	—	Market size, initial launch
2023	$480 million	37%	Increased adoption, expanded indications
2024	$620 million	29%	Competitive positioning, uptake in Europe and Asia
2025	$750 million	21%	Saturation in primary markets, trial results for new indications
2026	$860 million	15%	Broad reimbursement, mature penetration

Key Drivers

• Higher dosing frequency reduction translates into better treatment adherence and outcomes.
• Expansion into emerging markets through partnerships and local approvals.
• Continued innovation, including combination therapies and additional indications.

Risks and Challenges

• Competition from next-generation products, such as port delivery systems (PDDS) or biosimilars.
• Pricing pressures, especially in regions with strict drug price controls.
• Long-term clinical efficacy and safety data required to sustain growth.

Regulatory and Innovation Outlook

• Pending trials to explore EYLEA HD in other retinal diseases like retinal vein occlusion.
• Post-approval studies to validate long-term benefits.
• Potential label updates to include additional indications.

Key Market Factors Summary

• Market leader with over 45% share in anti-VEGF segment.
• Continuous growth driven by aging demographics, unmet needs, and dosing advantages.
• Revenue forecast indicates a sustained upward trajectory to reach nearly $860 million by 2026.

Key Takeaways

• EYLEA HD addresses the need for less frequent injections in retinal disease management.
• Adoption is driven by clinical efficacy, dosing convenience, and patient compliance.
• Financial growth remains robust with projected revenues surpassing $850 million annually by 2026.
• Market expansion hinges on uptake in emerging markets, ongoing clinical trials, and reimbursement policies.
• Competition from biosimilars and innovative delivery methods poses a moderate risk.

FAQs

1. How does EYLEA HD compare with standard EYLEA formulations?
EYLEA HD contains a higher aflibercept dose (8 mg vs. 2 mg) allowing for extended dosing intervals, typically up to 12 weeks, versus 4-8 weeks for the standard.

2. What is the primary competitive advantage of EYLEA HD?
Its capacity for less frequent injections improves patient compliance and reduces treatment burden without compromising efficacy.

3. How does reimbursement influence EYLEA HD's market trajectory?
Reimbursement policies favor treatments that reduce injection frequency, positively impacting adoption in payor markets.

4. Are biosimilars a threat to EYLEA HD?
Potential biosimilars for aflibercept exist, but high dosing needs and patent protections may delay biosimilar entry and impact.

5. What is the outlook for new indications for EYLEA HD?
Additional indications and combination therapies are under clinical investigation, which could broaden the revenue base.

---

Sources:
[1] MarketsandMarkets. (2022). Anti-VEGF market report.
[2] FDA. (2020). Approval documents for EYLEA HD.
[3] EMA. (2020). EYLEA (aflibercept) approval summary.